Efficacy and Safety of Weekly Liquid Alendronate in Korean Postmenopausal Women with Osteoporosis: a 12-month, Multi-center, Randomized Trial

Overview

Journal Arch Osteoporos

Publisher Springer

Date 2024 Nov 26

PMID 39589664

Authors

Seungjin Baek

Seong Hee Ahn

Namki Hong

Da Hea Seo

Seongbin Hong

Yumie Rhee

Affiliations

Soon will be listed here.

Abstract

Purpose/introduction: Alendronate, despite its significant efficacy, poses challenges due to complex administration protocols and patient compliance issues, underscoring the need for various formulations. This study compared the efficacy and safety of once-weekly low-volume liquid alendronate sodium trihydrate (ALN-S), an oral solution, to once-weekly alendronate sodium (ALN-T), an oral tablet, in Korean postmenopausal women with osteoporosis.

Methods: In a 12-month, multi-center, prospective, randomized, open-labeled, parallel trial conducted at two hospitals in Korea, 170 patients were randomized to alendronate solution (ALN-S) (N = 85) or alendronate tablet (ALN-T) (N = 85) groups. The bone mineral density (BMD) of the lumbar spine (LS), femoral neck (FN), and total hip (TH) was measured at baseline and after 12 months. Bone turnover markers (BTMs) were assessed at baseline, 6, and 12 months. The primary outcome was the percentage change in BMD of the LS, evaluated for non-inferiority.

Results: After 12 months, both ALN-S and ALN-T groups exhibited a significant increase in LS, FN, and TH BMD, with no significant intergroup differences (ALN-S: LS 5.0 ± 0.6%, FN 1.8 ± 0.6%, TH 2.2 ± 0.5%; ALN-T: LS 5.2 ± 0.6%, FN 1.6 ± 0.6%, TH 1.8 ± 0.5%). ALN-S was found to be non-inferior to ALN-T for BMD change at LS (treatment difference: - 0.22%, 95% CI: - 1.84 to 1.40%), excluding the predefined non-inferiority margin of - 2.29%. Changes in BTMs did not differ significantly between groups. The frequency of adverse events was similar between groups.

Conclusion: Liquid alendronate was non-inferior to tablet alendronate in increasing BMD in Korean postmenopausal women with osteoporosis, presenting a viable alternative when the tablet form is limited in various clinical scenarios.

Clinical Trial Registration: The trial was registered with ClinicalTrials.gov (NCT05387200).

References

Johnell O, Kanis J . Epidemiology of osteoporotic fractures. Osteoporos Int. 2004; 16 Suppl 2:S3-7. DOI: 10.1007/s00198-004-1702-6. View

Eastell R, Rosen C, Black D, Cheung A, Murad M, Shoback D . Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104(5):1595-1622. DOI: 10.1210/jc.2019-00221. View

Diez-Perez A, Naylor K, Abrahamsen B, Agnusdei D, Brandi M, Cooper C . International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017; 28(3):767-774. PMC: 5302161. DOI: 10.1007/s00198-017-3906-6. View

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006; 17(11):1645-52. DOI: 10.1007/s00198-006-0179-x. View

Invernizzi M, Cisari C, Carda S . The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin Exp Res. 2014; 27(2):107-13. DOI: 10.1007/s40520-014-0256-5. View

Giusti A, Bianchi G, Barone A, Black D . A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res. 2021; 33(9):2529-2537. DOI: 10.1007/s40520-020-01777-9. View

Okimoto N, Uemura Y, Yoshioka T, Arita S, Tsurukami H, Otomo H . Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open-label, prospective, observational study. Health Sci Rep. 2019; 2(1):e107. PMC: 6346986. DOI: 10.1002/hsr2.107. View

Coaccioli S, Celi G, Crapa M, Masia F, Brandi M . Alendronate soluble solution: a higher adherence rate in the treatment of osteoporosis. Clin Cases Miner Bone Metab. 2014; 11(2):123-5. PMC: 4172180. View

Brandi M, Black D . A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation. Clin Cases Miner Bone Metab. 2014; 10(3):187-90. PMC: 3917581. View

10.

Gomez Acotto C, Antonelli C, Flynn D, McDaid D, Roldan E . Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition. Calcif Tissue Int. 2012; 91(5):325-34. PMC: 3466430. DOI: 10.1007/s00223-012-9639-9. View

11.

Brown J, Prince R, Deal C, Recker R, Kiel D, de Gregorio L . Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2008; 24(1):153-61. DOI: 10.1359/jbmr.0809010. View

12.

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View

13.

McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J . Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004; 48(3):271-87. DOI: 10.1016/j.maturitas.2004.02.005. View

14.

Eastell R, Vittinghoff E, Lui L, McCulloch C, Pavo I, Chines A . Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res. 2021; 37(1):29-35. PMC: 9291617. DOI: 10.1002/jbmr.4433. View

15.

Cryer B, Binkley N, Simonelli C, Lewiecki E, Lanza F, Chen E . A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother. 2005; 3(3):127-36. DOI: 10.1016/s1543-5946(05)80019-4. View